PR Newswire NEW YORK, Sept. 12, 2024 NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Report with the AI impact on market trends- The global femtech devices market size is estimated to grow by USD 8.6 billion from 2024-2028, according to Technavio. ...
PR Newswire WASHINGTON, Sept. 12, 2024 Obesity Rates are Predominantly Highest in Communities Experiencing Barriers to Healthy Eating and Those with Few Opportunities for Physical Activity WASHINGTON, Sept. 12, 2024 /PRNewswire/ -- ...
PR Newswire WILMINGTON, N.C., Sept. 10, 2024 Health Food Franchise Plans Fresh Initiatives to Bring America's Youth into the Clean Eating Conversation WILMINGTON, N.C., Sept. 10, 2024 /PRNewswire/ -- The Clean Eatz Foundation, which acts ...
PR Newswire AUCKLAND, New Zealand, Sept. 10, 2024 AUCKLAND, New Zealand, Sept. 10, 2024 /PRNewswire/ -- A new study published in Obesity Pillars adds to the growing evidence behind Calocurb, a clinically proven natural GLP-1 activator ...
PR Newswire CAMBRIDGE, Mass., Sept. 4, 2024 CAMBRIDGE, Mass., Sept. 4, 2024 /PRNewswire/ -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on discovery, development and commercialization of novel oral therapies for the ...
PR Newswire TAMPA, Fla., Aug. 29, 2024 TAMPA, Fla., Aug. 29, 2024 /PRNewswire/ -- The Obesity Action Coalition (OAC) commends the Biden Administration for raising awareness of the need to expand access to obesity care and reduce the high ...
PR Newswire CRANBURY, N.J., Aug. 22, 2024 CRANBURY, N.J., Aug. 22, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
PR Newswire BLOOMINGTON, Minn., Aug. 19, 2024 While the cost of these weight loss drug medications is high, HealthEZ notes employers could see long-term savings when coupled with smart weight loss behavioral programs — but a strong wellness ...
PR Newswire TEL-AVIV, Israel and RALEIGH, N.C., Aug. 19, 2024 The global obesity-diabetes drugs market is projected to be worth around $100 billion by 2034[1] – largely driven by Glucagon-like peptide-1 (GLP-1) inhibitors like Novo Nordisk's ...
PR Newswire CAMBRIDGE, Mass., Aug. 13, 2024 No Significant Issues Encountered During the Single Ascending Dose (SAD) Study, Allowing for Previously Reported Accelerated Start to Multiple Ascending Dose (MAD) Part 2 Top Line Data Readout ...
Soumya Swaminathan, former WHO Chief Scientist, highlights that the rise in abdominal obesity in India is largely due to unhealthy diets and a lack of physical activity, pointing to a significant public health concern ( ). ...
Essential need to preserve skeletal muscle mass when using GLP-1 receptor agonists for weight loss has been highlighted in the Lancet editorial. Although effective for obesity treatment, these medications raise concerns over the potential for ...
Expanding access to new and highly effective weight-loss medications could save over 40,000 deaths every year in the United States ( ). A recent study by the Yale School of Public Health and the University of Florida, explains the ...
New blood test has been developed that measures lipids to identify children at risk of obesity-related complications, including type 2 diabetes , liver disease , and heart disease , as per a study from King’s College London published in Nature ...
A BMJ investigation has uncovered a widespread lack of access to obesity care in England. Nearly half of the country's patients cannot see specialist weight loss teams, and...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers